Clarity Pharmaceuticals has signed a commercial-scale supply agreement for copper-64 (Cu-64) production with radioisotope producer Nusano, effective April 16.
Nusano's 190,000 sq ft state-of-the-art facility in West Valley City, Utah is expected to begin production in 2025, with Cu-64 isotope supply planned to begin in early 2026. The Nusano facility is capable of producing more than 1,000 Ci (37,000 GBq) of Cu-64 per day at capacity. This translates into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life.
Nusano is also developing in-house production of the target material for Cu-64 manufacturing, nickel-64 (Ni-64), and plans to start producing Cu-67 and actinium-225 (Ac-225 or) isotopes in 2025 and 2026. Both of these isotopes are used in Clarity's pipeline of theranostic products in development.
The supply agreement is effective for an initial period of three years with automatic renewal for successive two-year periods.
